Klinik Hirslanden, Zurich Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
1998
NCT00003230
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Alternative names

Gerhard Treiber | Lung Center Hirslanden, Zuerich, Switzerland | Treiber, Gerhard

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Hepatocellular (Phase 2)

Leukemia (Phase 2)

Leukemia, Hairy Cell (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Liver Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 5